Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02254993 · ClinicalTrials.gov registry record · Phase 2
Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses
A Phase 2 study, sponsored by Armata Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT02254993 is a Phase 2 study that has completed, run by Armata Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT02254993, a Phase 2 study, has completed, sponsored by Armata Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
Part A: Open-label, multiple arm, safety, microbiology and pharmacokinetic (PK) study in healthy adult male and female subjects 18-75 years of age. All subjects will be assessed for safety and microbiology parameters. A subset of subjects will be assessed for pharmacokinetic parameters. No longer enrolling study subjects in Part A. Part B: Open-label, multiple arm, safety and microbiology study in healthy adult male and female subjects 18-75 years of age. All subjects will be assessed for safety, pharmacokinetic, and microbiology parameters.
Interventions
- DRUG C16G2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02254993
The ClinicalTrials.gov registry entry for NCT02254993 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Armata Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which C16G2 is the first listed.
NCT02254993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02254993 about?
NCT02254993 is a clinical study titled "Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses". Part A: Open-label, multiple arm, safety, microbiology and pharmacokinetic (PK) study in healthy adult male and female subjects 18-75 years of age. All subjects will be assessed for safety and microbiology parameters. A subset of subjects will be assessed for pharmacokinetic parameters. No longer en...
What is the current status of trial NCT02254993?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2014-10. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02254993?
The interventions under investigation include: C16G2 (DRUG).
Who is sponsoring clinical trial NCT02254993?
This trial is sponsored by Armata Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.